03:22:55 EDT Sat 17 Apr 2021
Enter Symbol
or Name

Z:LLY - ELI LILLY AND COMPANY - http://www.lilly.com03:22:55 EDT
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
LLY - Z0.4188.60·189.901.0189.25+3.331.83,732.0705,78948,080187.38  190.30  186.88218.00  129.2119:59:4506:3015 min RT 2¢

Recent Trades - Last 10 of 48080
Time ETExPriceChangeVolume

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent BulletinsNews ReleasesIn The NewsOther
Date ETSymbolTypeHeadline
2021-04-16 06:30U:LLYNews ReleaseLilly requests revocation of emergency use authorization for bamlanivimab alone to complete transition to bamlanivimab and etesevimab together for treatment of COVID-19 in the U.S.
2021-04-13 06:30U:LLYNews ReleaseDiogo Rau to join Lilly as Senior Vice-President and Chief Information and Digital Officer
2021-04-12 06:45U:LLYNews ReleaseLilly modified COVID-19 purchase agreement for bamlanivimab alone with the U.S. government and is focusing on supply of bamlanivimab and etesevimab together
2021-04-11 14:00U:LLYNews ReleaseLilly Presents New Data on Retevmo ® (selpercatinib) in Advanced RET Fusion-Positive Gastrointestinal and Other Cancers at 2021 American Association for Cancer Research (AACR) Annual Meeting
2021-04-08 06:45U:LLYNews ReleaseLilly and Incyte announce results from the Phase 3 COV-BARRIER study of baricitinib in hospitalized COVID-19 patients
2021-04-06 16:30U:LLYNews ReleaseLilly and Incyte communicate review extension of supplemental New Drug Application for baricitinib for the treatment of moderate to severe atopic dermatitis
2021-04-06 14:30U:LLYNews ReleaseLilly Confirms Date and Conference Call for First-Quarter 2021 Financial Results Announcement
2021-04-01 08:00U:LLYNews ReleaseLilly to Host Sustainability Webcast to Provide Overview of Environmental, Social and Governance (ESG) Efforts
2021-03-31 08:30U:LLYNews ReleaseSurvey reveals healthcare professionals believe greater collaboration is needed to improve patient outcomes in diabetes care
2021-03-29 08:30U:LLYNews ReleaseLilly, Vir Biotechnology and GSK Announce Positive Topline Data from the Phase 2 BLAZE-4 Trial Evaluating Bamlanivimab with VIR-7831 in Low-Risk Adults with COVID-19